CN106488777A - 用于心脏肥大治疗和诊断的LncRNA - Google Patents

用于心脏肥大治疗和诊断的LncRNA Download PDF

Info

Publication number
CN106488777A
CN106488777A CN201580033597.2A CN201580033597A CN106488777A CN 106488777 A CN106488777 A CN 106488777A CN 201580033597 A CN201580033597 A CN 201580033597A CN 106488777 A CN106488777 A CN 106488777A
Authority
CN
China
Prior art keywords
lncrna
expression
seq
compound
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580033597.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·图姆
K·雷加拉
J·菲尔埃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Priority to CN202310780826.3A priority Critical patent/CN117224687A/zh
Publication of CN106488777A publication Critical patent/CN106488777A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580033597.2A 2014-04-22 2015-04-22 用于心脏肥大治疗和诊断的LncRNA Pending CN106488777A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310780826.3A CN117224687A (zh) 2014-04-22 2015-04-22 用于心脏肥大治疗和诊断的LncRNA

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14165504.3 2014-04-22
EP14165504 2014-04-22
PCT/EP2015/058684 WO2015162161A1 (en) 2014-04-22 2015-04-22 Lncrnas for therapy and diagnosis of cardiac hypertrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310780826.3A Division CN117224687A (zh) 2014-04-22 2015-04-22 用于心脏肥大治疗和诊断的LncRNA

Publications (1)

Publication Number Publication Date
CN106488777A true CN106488777A (zh) 2017-03-08

Family

ID=50630577

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580033597.2A Pending CN106488777A (zh) 2014-04-22 2015-04-22 用于心脏肥大治疗和诊断的LncRNA
CN202310780826.3A Pending CN117224687A (zh) 2014-04-22 2015-04-22 用于心脏肥大治疗和诊断的LncRNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310780826.3A Pending CN117224687A (zh) 2014-04-22 2015-04-22 用于心脏肥大治疗和诊断的LncRNA

Country Status (10)

Country Link
US (4) US20170183652A1 (https=)
EP (2) EP3134526B1 (https=)
JP (2) JP6577960B2 (https=)
CN (2) CN106488777A (https=)
DK (2) DK3467111T3 (https=)
ES (2) ES2706878T3 (https=)
HU (2) HUE041700T2 (https=)
PL (2) PL3134526T3 (https=)
TR (1) TR201818825T4 (https=)
WO (1) WO2015162161A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107326072A (zh) * 2017-06-23 2017-11-07 陈梦麟 Linc00702及其在调控心血管系统中的应用
CN110878348A (zh) * 2019-11-19 2020-03-13 南京启医科技有限公司 一种具有较高特异性的心衰lnc RNA生物标志物及其检测方法和应用
CN112494651A (zh) * 2020-09-30 2021-03-16 吉林大学 lncRNA H19作为分子靶点在动脉粥样硬化治疗中的应用
CN114959008A (zh) * 2022-04-20 2022-08-30 华中科技大学同济医学院附属协和医院 长链非编码RNA-lnc-TSI的用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608907D0 (en) * 2016-05-20 2016-07-06 Ucl Business Plc Means for modulating gene expression
EP3638787A1 (en) * 2017-06-12 2020-04-22 Firalis SA Diagnostic, prognostic and therapeutic uses of long noncoding rnas for pathologies and toxicities inducing heart disorders
CA3067910A1 (en) * 2017-06-19 2018-12-27 Universite De Lausanne Methods and compositions for controlling cardiac fibrosis and remodeling
WO2019014656A1 (en) 2017-07-14 2019-01-17 Han Si Ping METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
EP3665281A4 (en) * 2017-08-10 2021-05-05 City of Hope CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY
CN113166750B (zh) 2018-08-10 2025-02-18 希望之城 可编程的条件性sirna及其用途
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
CN110229879B (zh) * 2019-07-01 2022-11-18 青岛大学 一种piRNA-500核苷酸类似物及其反义核苷酸的应用和应用其的产品
CN111690673A (zh) * 2020-06-22 2020-09-22 扬州大学 一种lncRNA通过编码小肽促进PGCs形成的验证方法
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
IL301675A (en) 2020-10-09 2023-05-01 Tenaya Therapeutics Inc Methods and preparations for placophilin-2 gene therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325451A (zh) * 1998-09-11 2001-12-05 加利福尼亚大学董事会 能在心脏中组织特异性表达的重组腺病毒
WO2004031359A2 (en) * 2002-10-03 2004-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulating expression genes
WO2008104290A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft H19 as a biomarker for ppara modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
WO2002092124A1 (en) * 2001-05-11 2002-11-21 Wyeth Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof
GB0112343D0 (en) 2001-05-21 2001-07-11 Norske Stats Oljeselskap Well treatment
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325451A (zh) * 1998-09-11 2001-12-05 加利福尼亚大学董事会 能在心脏中组织特异性表达的重组腺病毒
WO2004031359A2 (en) * 2002-10-03 2004-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulating expression genes
WO2008104290A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft H19 as a biomarker for ppara modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIELA TIRZIU等: "Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice", 《J CLIN INVEST.》 *
KENNETH WALSH等: "Cardiac growth and angiogenesis coordinated by intertissue interactions", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
STRAUSBERG,R.L.等: "Homo sapiens H19, imprinted maternally expressed untranslated mRNA, mRNA (cDNA clone IMAGE:4995493), partial cds", 《GENBANK》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107326072A (zh) * 2017-06-23 2017-11-07 陈梦麟 Linc00702及其在调控心血管系统中的应用
CN110878348A (zh) * 2019-11-19 2020-03-13 南京启医科技有限公司 一种具有较高特异性的心衰lnc RNA生物标志物及其检测方法和应用
CN110878348B (zh) * 2019-11-19 2023-03-28 南京启医科技有限公司 一种具有较高特异性的心衰lnc RNA生物标志物及其检测方法和应用
CN112494651A (zh) * 2020-09-30 2021-03-16 吉林大学 lncRNA H19作为分子靶点在动脉粥样硬化治疗中的应用
CN114959008A (zh) * 2022-04-20 2022-08-30 华中科技大学同济医学院附属协和医院 长链非编码RNA-lnc-TSI的用途

Also Published As

Publication number Publication date
JP2020007332A (ja) 2020-01-16
ES2706878T3 (es) 2019-04-01
EP3467111B1 (en) 2021-12-15
DK3467111T3 (da) 2022-03-14
WO2015162161A1 (en) 2015-10-29
JP6805304B2 (ja) 2020-12-23
HUE041700T2 (hu) 2019-05-28
US20170183652A1 (en) 2017-06-29
CA2945559A1 (en) 2015-10-29
HUE057484T2 (hu) 2022-05-28
EP3134526B1 (en) 2018-10-31
US20200165604A1 (en) 2020-05-28
JP6577960B2 (ja) 2019-09-18
US20220315924A1 (en) 2022-10-06
TR201818825T4 (tr) 2019-01-21
PL3134526T3 (pl) 2019-04-30
US11371043B2 (en) 2022-06-28
US20220348920A1 (en) 2022-11-03
JP2017514813A (ja) 2017-06-08
EP3467111A1 (en) 2019-04-10
EP3134526A1 (en) 2017-03-01
ES2906995T3 (es) 2022-04-21
DK3134526T3 (en) 2019-02-04
PL3467111T3 (pl) 2022-04-11
CN117224687A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
CN106488777A (zh) 用于心脏肥大治疗和诊断的LncRNA
JP5871791B2 (ja) 心不全または心不全の危険性を中和、予防および／または決定する手段および方法
WO2008029790A1 (fr) Nouvel acide nucléique
WO2008084319A2 (ja) 新規核酸
CN104548134A (zh) miR-144及其抑制剂的应用
EP2314678B1 (en) Micro-rna associated with rheumatoid arthritis
US20190153446A1 (en) Mir-149-3p and method for treating metabolic disease using the same
Lin et al. Circular RNA circ_0001006 aggravates cardiac hypertrophy via miR-214-3p/PAK6 axis
CN118512469A (zh) 包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
CN115052590A (zh) 包含8-氧代鸟嘌呤的RNA干扰诱导核酸、与包含8-氧代鸟嘌呤的microRNA结合的修饰的核酸及它们的用途
JP2020513407A (ja) 心臓細胞の機能を調節する方法、関連ヌクレオチドおよび化合物
KR20180092378A (ko) miR-130a를 유효성분으로 함유하는 방사선 민감성 증진용 조성물
JP5572814B2 (ja) 未分化細胞の心筋分化活性検出用マーカー、核酸分子、プライマーペア、キット、心筋分化抑制剤、未分化細胞の心筋分化活性検出方法、心筋分化活性を有する細胞の単離方法、未分化細胞の心筋分化活性のモニタリング方法、および未分化細胞の心筋分化の抑制方法
CN110923313B (zh) LncRNA的检测及其在骨质疏松诊治中的应用
CA2945559C (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
CN110184271A (zh) 一种mRNA-like ncRNA、抑制其表达的反义RNA及两者的应用
HK40104753A (zh) 用於心脏肥大治疗和诊断的lncrna
HK40006990B (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
HK40006990A (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
CN107254537A (zh) miR‑1912及其靶基因在诊治心肌梗死中的应用
Shephard Severe hypertrophic cardiomyopathy and heart failure caused by multiple mutations: from molecular pathogenesis to pharmacological intervention
US9212387B2 (en) Method for detection of genes targeted by microRNA
HK1233678B (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy
HK1233678A1 (en) Lncrnas for therapy and diagnosis of cardiac hypertrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170308

RJ01 Rejection of invention patent application after publication